Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
May 9, 2017
Revance Releases First Quarter 2017 Results
May 1, 2017
Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
April 25, 2017
Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017
March 7, 2017
Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
March 3, 2017
Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
February 27, 2017
Revance Releases Fourth Quarter and Full Year 2016 Results
February 22, 2017
Revance to Participate in Upcoming Investor Conferences
February 16, 2017
Revance Therapeutics to Release Fourth Quarter 2016 Financial Results Monday, February 27, 2017
January 26, 2017
BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017
January 18, 2017
Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
Displaying 191 - 200 of 288